Given the evolving on-ground situation and newer variant-led infections, the pandemic is far from over. In such a scenario, for businesses to stay relevant, we will need to be flexible and more adaptable to the changes that need to be embraced to keep core business growth drivers resilient. In 2022, the pharma industry will continue to reimagine itself while driving growth and boosting value through:

Purposeful collaborations to provide access

The pandemic has been a great example of large-scale collaborations. We have not only seen industries collaborating to provide better access to treatments, but the power of one has been observed across sectors, government, public and private institutions. The industry came together in solidarity to ensure patients had access to essential drugs round-the-clock, and we did so by forging global partnerships, lending innovations and also sharing manufacturing sites and distribution networks. In 2022, a greater force of meaningful and purposeful partnerships can be foreseen where companies will come together to provide access to treatments and technologies.

Accelerated digital transformation to drive value

With the help of digital and its further advancements in pharma and healthcare, the future will continue to be driven by artificial intelligence (AI) and machine learning (ML).

Right from the identification of the disease, personalised forms of treatment, drug discovery and manufacturing to using data effectively for clinical trials and forecasting, AI and ML are going to continue to drive the future of pharma.

Enabling a mindset shift from illness to wellness

During the pandemic situation, health has taken  center stage and the disruption that is continued to be seen is the behavioral shift – how individuals take ownership of their well-being; thus leading to a conscious shift from ‘illness to wellness’ wherein patients are more aware and empowered about their health needs. The opportunity here is for pharma companies to continue to reimagine their roles in the lives of patients and play a larger part going beyond just being a medicine maker.

The pharma industry has been a driving force to ensure the availability of treatments and critical drugs – during Covid-19 and beyond. The swift recalibration amidst challenging times has showcased that the industry has unlimited potential.

Reference:
https://www.fortuneindia.com/enterprise/predictions-2022-the-pandemic-and-beyond-how-the-pharma-industry-is-shaping-up-for-the-future/106491

More News
Global Freight Costs Surge 130%
News · 03/11/2026

Global shipping costs have climbed to $4,000–$4,500 in October from $2,000–$2,500 in February 2026. Freight rates, which had eased through much of 2025 and early 2026 as the demand-supply balance improved, have rebounded sharply in recent months. The increase has brought shipping costs back into focus for businesses dependent on international cargo movement.

READ MORE
FDA Issues Final Guidance on Manufacturing Changes for Biosimilars
News · 03/11/2026

The U.S. Food and Drug Administration (FDA) has finalized guidance outlining how manufacturers should report post-approval manufacturing changes for biosimilar and interchangeable biosimilar products. The guidance provides greater regulatory clarity on changes involving production processes, manufacturing sites, analytical methods, raw materials, and process controls. It aims to ensure product quality while reducing unnecessary regulatory burden.

READ MORE
Biosimilars |  Regulatory Reforms & a Maturing Patent Framework
News · 01/10/2026

A significant uptick in M&A activity in the biosimilars sector is being driven by FDA regulatory reforms, a maturing patent litigation framework and a looming patent cliff — $200 billion of branded products are facing patent expiration by 2030.

READ MORE
Container Rates Edge Lower Ahead of Golden Week as Suez Traffic Returns
News · 01/10/2026

The Drewry World Container Index edged lower this week as falling Asia-Europe rates outweighed firmer pricing on the Transpacific, with carriers preparing another round of blank sailings ahead of China’s Golden Week holiday.

READ MORE
EU: “Forever Chemicals” in a Conflict of Interests
News · 01/09/2026

On 14 July 2026, the European Parliamentary Research Service (EPRS) published a comprehensive briefing on PFAS (per- and polyfluoroalkyl substances), also known as ‘forever chemicals’. The document is intended to serve as a technical basis for MEPs in their upcoming political decisions on PFAS regulation and summarises the current state of scientific knowledge, regulation and procedures.

READ MORE
China Port Congestion
News · 01/09/2026

Following a series of typhoon disruptions in East China during the month of August, major ports including Shanghai and Ningbo continue to experience congestion and operational recovery challenges. Industry reports indicate that vessel schedules, yard operations, and equipment circulation remain affected as terminals work through accumulated backlogs from successive storm events.

READ MORE
EU Microplastics Restriction
News · 03/08/2026

Under REACH Annex XVII Entry 78, the EU has banned the placing on the market of synthetic polymer microparticles (SPMs) unless a specific derogation applies. Derogations exist for essential uses such as:

READ MORE
CLP 2026: New Hazard Classes For Mixtures
News · 02/07/2026

As a result of the amendment of the CLP Regulation (Regulation (EC) No 1272/2008 on the classification, labelling and packaging of substances and mixtures), new hazard classes have entered into force.

READ MORE
EU & US Move to Phase Out Animal Testing
News · 05/06/2026

In a converging policy shift on both sides of the Atlantic, European regulators this week published a roadmap toward fully replacing animal testing for chemical safety assessments, while the US Environmental Protection Agency issued a rare update to its list of alternative test methods.

READ MORE